Format

Send to

Choose Destination
J Neuroimmunol. 2015 Aug 15;285:180-6. doi: 10.1016/j.jneuroim.2015.06.006. Epub 2015 Jun 19.

Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

Author information

1
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: maria.alme@uib.no.
2
Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: Agnes.elisabeth.nystad@helse-bergen.no.
3
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: lars.bo@helse-bergen.no.
4
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: kjell-morten.myhr@helse-bergen.no.
5
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway. Electronic address: christian.alexander.vedeler@helse-bergen.no.
6
Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: stig.wergeland@helse-bergen.no.
7
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: oivind.torkildsen@helse-bergen.no.

Abstract

Fingolimod (FTY720) is approved for treatment of relapsing-remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected any positive effect on cerebral remyelination. The discrepant findings could be a result of different mechanisms underlying cerebral and cerebellar remyelination. The cuprizone model for de- and remyelination was used to evaluate whether fingolimod had an impact on cerebellar remyelination in vivo. We found that fingolimod did not have any effect on cerebellar remyelination, number of mature oligodendrocytes, microglia or astrocytes when fed after cuprizone exposure.

KEYWORDS:

Cerebellum; Cuprizone; Demyelination; FTY720; Fingolimod; Remyelination

PMID:
26198937
DOI:
10.1016/j.jneuroim.2015.06.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center